Aprepitant is the first commercially available drug of a new class of neurokinin-1–receptor antagonists for treating chemotherapy-induced nausea and vomiting. The dominant ligand for the neurokinin-1 ...
Aprepitant (Emend, Merck & Co.), which is already approved for use in adults for the prevention of chemotherapy-induced nausea and vomiting (CINV), has now been shown to also be effective in children ...
The supportive care of patients receiving antineoplastic treatment has dramatically improved over the past two decades. The development of effective means to prevent nausea and vomiting arising from ...
Learn everything you need to know about Aprepitant-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the ...
Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-of-Life Outcomes Patients ...
APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 (“NK-1”) antagonist indicated for the prevention of PONV in adults, with a long half-life and quicker ...
Aprepitant is associated with improved survival outcomes in early-stage breast cancer, particularly in triple-negative cases, showing significant DDFS and BCSS improvements. The study analyzed 13,811 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results